Tollovid + Rebounders

Exploring Viral Persistence after a paxlovid rebound

We're excited to learn how Tollovid is positively impacting those suffering from ongoing PASC symptoms after experiencing a Paxlovid Rebound.

Rebounding is when a patient who, after receiving a full five-day course of Paxlovid treatment, either has a reemergence of COVID symptoms or tests positive after a previous, negative test. Patients with evidence of persistent virus expression went on to develop conditions typical of long Covid, including brain fog, fatigue, and loss of smell.

WHAT IS A PAXLOVID REBOUND?

The CDC defines Paxlovid rebound* as when a patient who, after receiving a full five-day course of treatment, either has a reemergence of COVID symptoms or tests positive after a previous, negative test. Under this classification, when you rebound, “you can have virus without symptoms, symptoms without virus, and you can have the two together.

HOW DOES TOLLOVID HELP?

Rebound may occur because some patients are not receiving high enough doses of the protease inhibitor, the part that targets COVID enzymes. Rebounding is not necessarily a result of the virus becoming resistant to the drug, but that experiencing a lower dose could lead to pockets of virus surviving through the treatment and then reemerging days later. Because Tollovid is a naturally-derived 3CL protease inhibitor, it can step in where Paxlovid leaves off and allow the patient to continue maximum treatment for a longer duration than just the recommended 5 days for Paxlovid.

Sources: https://www.scientificamerican.com/article/what-is-paxlovid-rebound-and-how-common-is-it/

Observational Study Data: Key Highlights

Case Study Data: April - June 20, 2022 n = 41

Please note that our market studies are still ongoing. Please see MyTollovid.com for the latest information as it becomes available.These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure,or prevent any disease.

94%

of Acute COVID-19 respondents reported
a decrease in Acute COVID Symptoms.

90%

of Long COVID (0-6 months) respondents reported a decrease in Long COVID Symptoms.
.

81%

of Long COVID (0-9 months) respondents reported a decrease in Long COVID Symptoms.

95%

of Acute COVID-19 respondents reported that they were happy with their results with Tollovid.

80%

of Long COVID (0-6 months) respondents reported that they were happy with their results.
.

67%

of Long COVID (0-9 months) respondents reported that they were happy with their results.

Download the Full Report

STUDY HIGHLIGHT:

A Case Study of Paxlovid Rebound Patient

“As of three days ago all her symptoms were resolved. She attributes this recovery to the treatment with Tollovid."

Symptoms Include: Fatigue, Tinnitus, Insomnia, Brain Fog, Fever, Joint Pain, Gastrointestinal Issues, Shortness of Breath, and Changes in Libido

Read the Full Study

How Tollovid™ Works:

1. Binding & Entry

First, the virus must get inside the cell. Every virus does this slightly differently, but most use their signature “spikes” to fuse themselves to a cell’s outer membrane and then squeeze their way inside.

2. POLYPEPTIDES

Once inside, the virus RNA instructs the cell to make a long polypeptide containing special enzymes. This long protein must be cut apart for the virus to replicate. To accomplish this, the virus encodes a special ‘scissors’, called 3CL protease, which cuts up the polypeptide into the different enzymes that then become functional.

3. Replication

Before these enzymes can start working, they need to be separated from each other. The protease enzyme acts like a pair of scissors, cutting the polypeptide up into the different enzymes that then become functional.

4. 3CL Protease Inhibitors

Protease inhibitors, like Tollovid, are designed to tightly bind to the protease enzyme, blocking its ability to cut. This shuts down the entire virus-making apparatus, leaving it unable to make a single virus.

Recommended Regimen

capsules

times per day

15+